Loading viewer...
investor_presentation
Format: PDF investor_presentation
8 FRANCO -NEVADA CORPORATION CONDENSED C ONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited, in millions of U.S. dollars) At September 30, At December 31, 2021 2020 ASSETS Cash and cash equivalents (note 4) $ 346.7 $ 534.2 Receivables 147.8 93.4 Loan receivable (note 5) 39.0
8 FRANCO -NEVADA CORPORATION
CONDENSED C ONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited, in millions of U.S. dollars)
At September 30, At December 31,
Cash and cash equivalents (note 4) $ 346.7 $ 534.2
Receivables 147.8 93.4
Loan receivable (note 5) 39.0 —
Prepaid expenses and other (note 6) 51.4 36.1
Current assets $ 584.9 $ 663.7
Royalty, stream and working interests, net (note 7) $ 5,124.6 $ 4,632.1
Investments and loan receivable (note 5) 205.2 238.4
Deferred income tax assets 51.2 45.1
Other assets (note 8) 18.8 13.6
Total assets $ 5,984.7 $ 5,592.9
Accounts payable and accrued liabilities $ 29.5 $ 40.8
Current income tax liabilities 13.6 12.4
Current liabilities $ 43.1 $ 53.2
Deferred income tax liabilities 108.4 91.5
Other liabilities 4.0 4.4
Total liabilities $ 155.5 $ 149.1
SHAREHOLDERS’ EQUITY
Share capital (note 16) $ 5,611.1 $ 5,580.1
Contributed surplus 18.7 14.0
Retained earnings (deficit) 321.3 (34.4)
Accumulated other comprehensive loss (121.9) (115.9)
Total shareholders’ equity $ 5,829.2 $ 5,443.8
Total liabilities and shareholders’ equity $ 5,984.7 $ 5,592.9
Commitments and contingencies (notes 20 and 21)
The accompanying notes are an integral part of these condensed consolidated financial statements and can be found in Q3/2021
Quarterly Report available on our website
Preview truncated — download the full document for the complete content.
presentation
investor_presentation
35 Pages
Suven Pharmaceuticals Ltd.
Tessco Technologies Investor Presentation — March 2018
investor_presentationinvestor_presentation
33 Pages
TESSCO Technologies, Incorporated